Avalanche Biotechnologies

February 4, 2019

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
June 25, 2015
Genentech and Regeneron win Thomson Reuters Allicense Awards for Top BioPharma Deals of the Year

Genentech and Regeneron win Thomson Reuters Allicense Awards for Top BioPharma Deals of the Year

The Intellectual Property and Science business of Thomson Reuters recently honoured Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for […]
Contact Us